ArticleEndocrine, metabolic & immune disorders drug targets2026
Stigmasterol, the Active Ingredient in Huanglian Decoction, Inhibits the MAOA-NF-κB-MLCK Pathway to Improve the Inflammation in Rats With Reflux Esophagitis.
Article in Endocrine, metabolic & immune disorders drug targets, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTraditional Chinese medicine (TCM) shows significant potential in treating reflux oesophagitis (RE).
methodsWe employed network pharmacology, metabolomics, and molecular docking to analyze the active ingredients and interaction targets of HD and RE. An
resultsNetwork pharmacology has identified monoamine oxidase A (MAOA) as a core target of HD in the treatment of RE. Metabolomic analysis revealed Stigmasterol to be the active component of HD. Functional studies demonstrated that HD and Stigmasterol enhanced cell viability in acid-exposed conditions, mitigated inflammation, and increased the expression of occludin, claudin- 1, and ZO-1, while simultaneously reducing levels of p-p65, MLCK, and MAOA. Molecular docking revealed that stigmasterol binds to MAOA. Notably, the protective effect of Stigmasterol on Het-1A was negated by the overexpression of MAOA. Furthermore, DISCUSSION: This study elucidates the role and mechanism of HD in RE. However, further clinical trials are needed to assess its applicability in clinical practice.
conclusionStigmasterol, the active ingredient in HD, inhibits the NF-κB-MLCK pathway via MAOA, thereby reducing RE-related cellular inflammation. This research offers novel insights for RE treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.